Brazilian field isolates project (ex vivo work)

Brazilian field isolates project (ex vivo work) – RD-16-1066. Malaria is one of the main public health problems in the world. The emergence of cases of resistance to available drugs makes the selection of new molecular targets in the parasite and the development of innovative chemotherapeutic agents against the disease extremely important. In this context, the search for drugs that act against different stages of the parasite’s life cycle and that have an elucidated mechanism of action is of fundamental importance. Testing of antimalarial compounds will be conducted in accordance with the “MMV Standard Terms and Conditions for Transfer of Materials” under Coordination in Brazil by Dr. Anna Caroline Campos Aguiar and Dr. Rafael Victorio Carvalho Guido. Ex vivo susceptibility testing of Plasmodium vivax and P. falciparum strains is based on inhibition of maturation of schizonts when treated with target compounds relative to drug-free controls. The project will be developed in collaboration with different national and international research centers, including: Center for Research and Innovation in Biodiversity and Pharmaceuticals – CIBFar-CEPID of the Institute of Physics of São Carlos-USP, Center for Research in Tropical Medicine of Rondônia- CEPEM (Porto Velho), FIOCRUZ-RO, FIOCRUZ-AM, Federal University of São Paulo (UNIFESP) and Medicines for Malaria Venture (MMV).

Project details

Drug-based Strategies
Product Development

Jun 2021

Brazil